AstraZeneca amends collaboration with Ironwood

Writer,

AstraZeneca has amended its collaboration agreement with Ironwood Pharmaceuticals in China mainland, China Hong Kong, and China Macau for Linzess.

This new agreement gives AstraZeneca full responsibility for developing, manufacturing, and commercialising Linzess in China.

Linzess is a first-in-class new treatment for patients with irritable bowel syndrome with constipation (IBS-C).

It is expected to be launched later this year, as Linzess was approved in China by the National Medical Products Administration in January 2019.

AstraZeneca will pay Ironwood three non-contingent payments, totalling $35m, between 2021 and 2024. In addition, Ironwood could receive up to $90m in milestone payments, contingent on the achievement of certain sales targets.


Related content

Redx Pharma inks licencing pact with AstraZeneca for fibrosis treatment

Drug developer Redx Pharma said it had signed a significant out-licensing agreement for its fibrotic diseases treatment with AstraZeneca.

AstraZeneca would take Redx Pharma's porcupine...

Tue, 04/08/2020 - 13:56


AstraZeneca prices $3bn bond offering

Drugmaker AstraZeneca said it had priced its bond offering totalling $3bn.

The three-tranched bond offering, expected to close on 6 August 2020, included $1.2bn...

Tue, 04/08/2020 - 07:41


Broker Forecast - Credit Suisse issues a broker note on AstraZeneca PLC

Credit Suisse today reaffirms its outperform investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 9500p (from 9000p).

Broker Forecasts data provided...

Mon, 03/08/2020 - 08:20


Broker Forecast - DZ Bank issues a broker note on AstraZeneca PLC

DZ Bank today reaffirms its sell investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 7500p (from 7300p).

Broker Forecasts data provided...

Fri, 31/07/2020 - 12:10


Broker Forecast - Barclays Capital issues a broker note on AstraZeneca PLC

Barclays Capital today reaffirms its overweight investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 9300p (from 9200p).

Broker Forecasts data provided...

Wed, 29/07/2020 - 08:20